Literature DB >> 16337151

Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials.

Elon Eisenberg1, Ewan D McNicol, Daniel B Carr.   

Abstract

UNLABELLED: Several reviews of randomized controlled trials (RCTs) have shown the efficacy of mu-opioids in reducing spontaneous neuropathic pain (NP). However, relatively little is known about their specific efficacy for evoked pain, which is a significant problem for many patients with NP. The present systematic review assesses the efficacy of opioid agonists for the treatment of evoked NP based upon published RCTs. We searched articles in any language using the MEDLINE database (1966 to December 2004), the Cochrane Central Register of Controlled Trials (4th quarter, 2004) and the reference lists of retrieved papers, employing search terms for RCTs, opioids and NP. Only RCTs in which opioid agonists were given to treat NP of any etiology, and evoked pain was assessed were included. Data were extracted by two independent investigators. Nine articles met inclusion criteria and were classified as short-term (less than 24h; n=7) or intermediate-term trials (4 weeks; n=2). Although the scarcity of retrieved data precluded formal meta-analysis of short-term trials, we found that the intensity of dynamic mechanical allodynia was significantly attenuated by opioids relative to placebo in all studies. In contrast, no consistent effects on the magnitude of static allodynia, the threshold for mechanical allodynia or the threshold or magnitude of heat allodynia were found. The threshold and magnitude of cold-induced allodynia generally responded positively to opioid treatments in patients with peripheral pain syndromes, but not central pain syndromes. Evoked pain was studied in only two intermediate-term trials, in both of which oxycodone was significantly superior to placebo. The results of the two trials were combinable for a meta-analysis that showed an overall 24 points difference in endpoint pain intensities between patients given opioids and those treated with placebo (95% CI -33 to -15; p<0.00001). IN
CONCLUSION: short-term studies show that opioids can reduce the intensity of dynamic mechanical allodynia and perhaps of cold allodynia in peripheral NP. Insufficient evidence precludes drawing conclusions regarding the effect of opioids on other forms of evoked NP. A meta-analysis of intermediate-term studies demonstrates the efficacy of opioids over placebo for evoked NP. These findings are clinically relevant because dynamic mechanical allodynia and cold allodynia are the most prevalent types of evoked pain in NP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16337151     DOI: 10.1016/j.ejpain.2005.10.007

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  12 in total

1.  Association of mu-opioid and NMDA receptors in the periaqueductal gray: what does it mean for pain control?

Authors:  Susan L Ingram
Journal:  Neuropsychopharmacology       Date:  2012-01       Impact factor: 7.853

Review 2.  New treatments for chronic prostatitis/chronic pelvic pain syndrome.

Authors:  Adam C Strauss; Jordan D Dimitrakov
Journal:  Nat Rev Urol       Date:  2010-02-09       Impact factor: 14.432

Review 3.  Behavioral models of pain states evoked by physical injury to the peripheral nerve.

Authors:  Linda S Sorkin; Tony L Yaksh
Journal:  Neurotherapeutics       Date:  2009-10       Impact factor: 7.620

4.  Sensory innervation of the dorsal longitudinal ligament and the meninges in the lumbar spine of the dog.

Authors:  Barbara Waber-Wenger; Franck Forterre; Kathrin Kuehni-Boghenbor; Renzo Danuser; Jens Volker Stein; Michael Hubert Stoffel
Journal:  Histochem Cell Biol       Date:  2014-04-20       Impact factor: 4.304

5.  Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia.

Authors:  Andrea L Schaffer; Nicholas A Buckley; Louisa Degenhardt; Briony Larance; Rose Cairns; Timothy A Dobbins; Sallie-Anne Pearson
Journal:  CMAJ       Date:  2018-03-26       Impact factor: 8.262

6.  Chronic inflammatory pain prevents tolerance to the antinociceptive effect of morphine microinjected into the ventrolateral periaqueductal gray of the rat.

Authors:  Melissa L Mehalick; Susan L Ingram; Sue A Aicher; Michael M Morgan
Journal:  J Pain       Date:  2013-10-22       Impact factor: 5.820

7.  GABAergic synaptic response and its opioidergic modulation in periaqueductal gray neurons of rats with neuropathic pain.

Authors:  Eu-Teum Hahm; Younghoon Kim; Jong-Ju Lee; Young-Wuk Cho
Journal:  BMC Neurosci       Date:  2011-05-12       Impact factor: 3.288

Review 8.  Peripheral afferents and spinal inhibitory system in dynamic and static mechanical allodynia.

Authors:  Jun-Ho La; Jin Mo Chung
Journal:  Pain       Date:  2017-12       Impact factor: 7.926

Review 9.  Intersection of chronic pain treatment and opioid analgesic misuse: causes, treatments, and policy strategies.

Authors:  Amy Wachholtz; Gerardo Gonzalez; Edward Boyer; Zafar N Naqvi; Christopher Rosenbaum; Douglas Ziedonis
Journal:  Subst Abuse Rehabil       Date:  2011-08-18

10.  Cohort protocol paper: the Pain and Opioids In Treatment (POINT) study.

Authors:  Gabrielle Campbell; Richard Mattick; Raimondo Bruno; Briony Larance; Suzanne Nielsen; Milton Cohen; Nicholas Lintzeris; Fiona Shand; Wayne D Hall; Bianca Hoban; Chyanne Kehler; Michael Farrell; Louisa Degenhardt
Journal:  BMC Pharmacol Toxicol       Date:  2014-03-20       Impact factor: 2.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.